Related Experiment Video
Updated: Apr 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Biologic response modifiers and pediatric psoriasis
Fernanda Bellodi Schmidt1, Kara N Shah1,2,3
1Division of Dermatology, Cincinnati Children's Hospital, Cincinnati, Ohio.
Abstract:
The efficacy and safety of biologic response modifiers such as etanercept, adalimumab, infliximab, and ustekinumab have been demonstrated in the treatment of psoriasis in adults, but none are currently approved for the treatment of psoriasis in children in the United States, and only etanercept is approved for the treatment of psoriasis in children in the European Union. Through case reports, case series, and a large clinical trial of the use of etanercept, the literature supports the use of these agents to treat psoriasis in children. Data on the use of the tumor necrosis factor-α antagonists etanercept, adalimumab, and infliximab in the treatment of other inflammatory diseases in children-namely Crohn's disease, juvenile arthritis, and uveitis--support their safety profile in children.
More Related Videos
06:09Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
Published on: June 22, 2016
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents